Germany-based medical device maker JenaValve Technology has extended its series C round, which featured a unit owned by China-based investment holding company Legend Holdings, to $72.5m.
Legend Capital invested in the $62.5m first close of the series C in July 2013, along with Edmond de Rothschild Investment Partners, Atlas Venture Fund, NeoMed Management, VI Partners, Sunstone Capital, Gimv, and Omega Funds. The extra $10m was provided by Valiance Asset Management and RMM.
Founded in 2006, JenaValve produces transcatheter aortic valve implantation (TAVI) systems to assist in aortic valve replacement for patients suffering heart problems. It said in July that it plans to use the funds to support clinical trials and the expansion of its commercial infrastructure, along with pursuing clinical initiatives in the US market and regulatory approval for its TAVI systems in China.
It raised €13.5m ($18.6m) in its series A round from Edmond de Rothschild and Atlas Venture in 2007, and a further €19m ($26.2m) in a series B led by VI and Sunstone in 2010.